A Study of TAS-120 in Patients With Metastatic Breast Cancer
Public ClinicalTrials.gov record NCT04024436. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Study of TAS-120 in Metastatic Breast Cancers Harboring Fibroblast Growth Factor Receptor (FGFR) Amplifications
Study identification
- NCT ID
- NCT04024436
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Taiho Oncology, Inc.
- Industry
- Enrollment
- 64 participants
Conditions and interventions
Interventions
- Futibatinib Drug
- Futibatinib plus Fulvestrant Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 27, 2020
- Primary completion
- May 30, 2023
- Completion
- Sep 5, 2023
- Last update posted
- Nov 12, 2025
2020 – 2023
United States locations
- U.S. sites
- 17
- U.S. states
- 8
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic - AZ | Phoenix | Arizona | 85054 | — |
| USCF | San Francisco | California | 94115 | — |
| Florida Cancer Specialists | Fort Myers | Florida | 33901 | — |
| Mayo Clinic - FL | Jacksonville | Florida | 32224 | — |
| Florida Cancer Specialists | St. Petersburg | Florida | 33705 | — |
| Florida Cancer Specialists | Tallahassee | Florida | 32308 | — |
| Moffitt Cancer Center | Tampa | Florida | 33612 | — |
| Florida Cancer Specialists | West Palm Beach | Florida | 33401 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| BIDMC | Boston | Massachusetts | 02115 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02115 | — |
| Mayo Clinic - MN | Rochester | Minnesota | 55905 | — |
| HCA Midwest Health | Kansas City | Missouri | 64132 | — |
| Tennessee Oncology | Chattanooga | Tennessee | 37404 | — |
| Tennessee Oncology | Nashville | Tennessee | 37203 | — |
| UT Southwestern | Dallas | Texas | 75390 | — |
| MD Anderson | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 20 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04024436, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 12, 2025 · Synced May 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04024436 live on ClinicalTrials.gov.